Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$21.70
-0.4%
$23.86
$14.97
$26.58
$2.66B0.721.11 million shs1.76 million shs
Microsoft Corporation stock logo
MSFT
Microsoft
$497.41
+0.3%
$452.23
$344.79
$500.76
$3.69T1.0321.66 million shs28.36 million shs
NIO Inc. stock logo
NIO
NIO
$3.44
-0.6%
$3.78
$3.02
$7.71
$7.22B1.6252.67 million shs24.39 million shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
-0.37%-1.90%-12.82%-9.28%+40.09%
Microsoft Corporation stock logo
MSFT
Microsoft
+0.30%+2.35%+8.42%+30.15%+11.29%
NIO Inc. stock logo
NIO
NIO
-0.72%+0.29%-3.10%-11.00%-17.31%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
4.9238 of 5 stars
3.61.00.03.93.43.33.8
Microsoft Corporation stock logo
MSFT
Microsoft
4.6775 of 5 stars
2.45.03.32.92.82.51.3
NIO Inc. stock logo
NIO
NIO
1.5207 of 5 stars
3.12.00.00.01.30.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
3.25
Buy$32.8351.31% Upside
Microsoft Corporation stock logo
MSFT
Microsoft
2.88
Moderate Buy$521.144.77% Upside
NIO Inc. stock logo
NIO
NIO
2.17
Hold$4.7437.87% Upside

Current Analyst Ratings Breakdown

Latest MSFT, NIO, and CPRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/30/2025
Microsoft Corporation stock logo
MSFT
Microsoft
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingPositive ➝ Positive
6/26/2025
Microsoft Corporation stock logo
MSFT
Microsoft
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$482.00 ➝ $530.00
6/25/2025
Microsoft Corporation stock logo
MSFT
Microsoft
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$515.00 ➝ $600.00
6/25/2025
Microsoft Corporation stock logo
MSFT
Microsoft
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$565.00 ➝ $585.00
6/17/2025
NIO Inc. stock logo
NIO
NIO
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSell ➝ Neutral$3.70 ➝ $3.80
6/13/2025
Microsoft Corporation stock logo
MSFT
Microsoft
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$515.00 ➝ $565.00
6/11/2025
Microsoft Corporation stock logo
MSFT
Microsoft
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$540.00 ➝ $605.00
6/5/2025
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/4/2025
Microsoft Corporation stock logo
MSFT
Microsoft
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
6/4/2025
NIO Inc. stock logo
NIO
NIO
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$4.00 ➝ $3.00
6/3/2025
NIO Inc. stock logo
NIO
NIO
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$4.00 ➝ $3.50
(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$491.73M5.38$2.44 per share8.90$6.10 per share3.56
Microsoft Corporation stock logo
MSFT
Microsoft
$245.12B15.08$14.90 per share33.38$36.12 per share13.77
NIO Inc. stock logo
NIO
NIO
$9.01B0.80N/AN/A$0.40 per share8.60
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
$163.89M$1.5713.8210.190.8936.91%42.45%36.59%8/6/2025 (Estimated)
Microsoft Corporation stock logo
MSFT
Microsoft
$88.14B$12.9438.4433.842.5235.79%32.74%18.13%7/29/2025 (Estimated)
NIO Inc. stock logo
NIO
NIO
-$3.06B-$1.62N/AN/AN/A-35.51%-286.45%-23.51%9/4/2025 (Estimated)

Latest MSFT, NIO, and CPRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/29/2025Q4 2025
Microsoft Corporation stock logo
MSFT
Microsoft
$3.35N/AN/AN/A$73.79 billionN/A
6/3/2025Q1 2025
NIO Inc. stock logo
NIO
NIO
-$0.22-$0.45-$0.23-$0.45$12.46 billion$1.66 billion
4/30/2025Q3 2025
Microsoft Corporation stock logo
MSFT
Microsoft
$3.22$3.46+$0.24$3.46$68.54 billion$70.07 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
N/AN/AN/AN/AN/A
Microsoft Corporation stock logo
MSFT
Microsoft
$3.320.67%N/A25.66%23 Years
NIO Inc. stock logo
NIO
NIO
N/AN/AN/AN/AN/A

Latest MSFT, NIO, and CPRX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/10/2025
Microsoft Corporation stock logo
MSFT
Microsoft
quarterly$0.830.71%8/21/20258/21/20259/11/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
N/A
6.14
5.96
Microsoft Corporation stock logo
MSFT
Microsoft
0.12
1.37
1.36
NIO Inc. stock logo
NIO
NIO
1.89
0.84
0.69

Institutional Ownership

CompanyInstitutional Ownership
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
79.22%
Microsoft Corporation stock logo
MSFT
Microsoft
71.13%
NIO Inc. stock logo
NIO
NIO
48.55%

Insider Ownership

CompanyInsider Ownership
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
10.40%
Microsoft Corporation stock logo
MSFT
Microsoft
0.03%
NIO Inc. stock logo
NIO
NIO
1.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Catalyst Pharmaceuticals, Inc. stock logo
CPRX
Catalyst Pharmaceuticals
80121.97 million109.29 millionOptionable
Microsoft Corporation stock logo
MSFT
Microsoft
228,0007.43 billion7.43 billionOptionable
NIO Inc. stock logo
NIO
NIO
45,6352.09 billion2.07 billionOptionable

Recent News About These Companies

NIO stock has halved. Could it double in future?
NIO (NYSE:NIO) Shares Up 2.8% - Here's Why
3 No-Brainer EV Stocks to Buy Right Now

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Catalyst Pharmaceuticals stock logo

Catalyst Pharmaceuticals NASDAQ:CPRX

$21.70 -0.08 (-0.37%)
As of 06/30/2025 04:00 PM Eastern

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Microsoft stock logo

Microsoft NASDAQ:MSFT

$497.41 +1.47 (+0.30%)
As of 06/30/2025 04:00 PM Eastern

Microsoft Corporation develops and supports software, services, devices and solutions worldwide. The Productivity and Business Processes segment offers office, exchange, SharePoint, Microsoft Teams, office 365 Security and Compliance, Microsoft viva, and Microsoft 365 copilot; and office consumer services, such as Microsoft 365 consumer subscriptions, Office licensed on-premises, and other office services. This segment also provides LinkedIn; and dynamics business solutions, including Dynamics 365, a set of intelligent, cloud-based applications across ERP, CRM, power apps, and power automate; and on-premises ERP and CRM applications. The Intelligent Cloud segment offers server products and cloud services, such as azure and other cloud services; SQL and windows server, visual studio, system center, and related client access licenses, as well as nuance and GitHub; and enterprise services including enterprise support services, industry solutions, and nuance professional services. The More Personal Computing segment offers Windows, including windows OEM licensing and other non-volume licensing of the Windows operating system; Windows commercial comprising volume licensing of the Windows operating system, windows cloud services, and other Windows commercial offerings; patent licensing; and windows Internet of Things; and devices, such as surface, HoloLens, and PC accessories. Additionally, this segment provides gaming, which includes Xbox hardware and content, and first- and third-party content; Xbox game pass and other subscriptions, cloud gaming, advertising, third-party disc royalties, and other cloud services; and search and news advertising, which includes Bing, Microsoft News and Edge, and third-party affiliates. The company sells its products through OEMs, distributors, and resellers; and directly through digital marketplaces, online, and retail stores. The company was founded in 1975 and is headquartered in Redmond, Washington.

NIO stock logo

NIO NYSE:NIO

$3.44 -0.02 (-0.58%)
As of 06/30/2025 03:58 PM Eastern

NIO Inc. designs, manufactures, and sells electric vehicles in the People's Republic of China. The company is also involved in the manufacture of e-powertrain, battery packs, and components; and racing management, technology development, and sales and after-sales management activities. In addition, it offers power solutions for battery charging needs; and other value-added services. The company was formerly known as NextEV Inc. and changed its name to NIO Inc. in July 2017. NIO Inc. was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.